Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$1.79 USD
-0.14 (-7.25%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.80 +0.01 (0.56%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RAPT 1.79 -0.14(-7.25%)
Will RAPT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RAPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RAPT
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
RAPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
Other News for RAPT
Barclays Remains a Hold on RAPT Therapeutics (RAPT)
Rapt Therapeutics price target lowered by $7 at Wells Fargo, here's why
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
RAPT Therapeutics GAAP EPS of -$0.71 beats by $0.05